Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Clin Chim Acta. 2011 Nov 20;412(23-24):2157-61. doi: 10.1016/j.cca.2011.07.024. Epub 2011 Aug 3.

Development of a point-of-care assay system for measurement of presepsin (sCD14-ST).

Author information

1
Research and Development Division, Mitsubishi Chemical Medience Corporation, Japan. okamura.yoshikazu@ma.medience.co.jp

Abstract

BACKGROUND:

The soluble CD14 subtype (sCD14-ST: renamed as presepsin) is a novel soluble CD14 molecule that is useful for diagnosing sepsis because sCD14-ST levels increase specifically in sepsis patients.

METHODS:

A fully automated PATHFAST® Presepsin assay system based on a chemiluminescent enzyme immunoassay was developed for detecting presepsin in human whole blood.

RESULTS:

The limit of blank, limit of detection, and limit of quantification were 2.33, 13.4, and 47.6 pg/ml, respectively. The assay linearity was achieved up to 20,000 pg/ml. Intra-assay imprecision was 3.4-4.8% for plasma and 2.7-7.1% for whole blood. Within-run imprecision and total imprecision for plasma were 3.6-4.4% and 5.2-6.5%, respectively. No interference was observed with bilirubin, hemoglobin, lipids, triglyceride, or rheumatoid factors. The reference intervals (95% percentile, n=127) were 333 pg/ml for plasma and 314 pg/ml for whole blood. The PATHFAST® Presepsin assay correlated well with a previously reported two-step presepsin ELISA (r=0.984, n=40). Furthermore, the concentration of presepsin was significantly higher in the sepsis group than in the healthy group.

CONCLUSION:

The PATHFAST® Presepsin assay performed well and can be used for point-of-care.

PMID:
21839732
DOI:
10.1016/j.cca.2011.07.024
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center